Polymyositis Treatment Market By Type Of Drug Class (Immunosuppressant, Alkylating Agent, Immunoglobulin, Monoclonal Antibodies, Corticosteroids) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027
Industry Outlook
Polymyositis treatment market projected to grow at a CAGR of 5.9% during the forecast period from 2019 to 2027. Polymyositis is rare connective tissue disease that causes muscle inflammation leading to muscle weakness. According to prevalence studies, globally the incidence of polymyositis is around 1 to 5 per 100,000 individuals and the prevalence is approximately 5 to 22 per 100,000 individuals. Thus, high awareness related to polymyositis diagnosis & treatment, strong drug pipeline, and rising geriatric population expected to assist the growth of polymyositis treatment market in the near future.
"Abatacept and octagam 10% expected to grow significantly throughout the forecast period for being highly efficient compared to currently available drugs"
Pipeline of polymyositis treatment is strong and comprises potential molecules that will drive the growth of overall market in the near future. Abatacept and octagam 10% are two most potential drugs under phase III clinical trials and anticipated to perform better than the drugs present currently in the market. Abatacept is a human fusion protein of CTLA-4 & the Fc portion of human IgG1 that inhibits the co-stimulation of T cells. Octagam is an immune globulin intravenous (human) and currently octagam 5% liquid approved for treatment of primary humoral immunodeficiency (PI) and other severe combined immunodeficiencies. However, its application for polymyositis treatment is under trial but results in Phase II trials have been satisfactory in recovery of immune system.
"Asia Pacific is the fastest growing market due to rising geriatric population in Japan and increasing awareness related to polymyositis treatment & diagnosis"
During the forecast period from 2019 to 2027, Asia Pacific identified as the fastest growing polymyositis treatment market mainly due to increasing awareness in medical practitioners related to polymyositis, and increasing geriatric population in Japan, China & South Korea. According to studies, in 2010 prevalence of polymyositis estimated to be 13.2 cases per 100,000 individuals in Japan. Japan identified as the largest polymyositis treatment market due to rising geriatric population, increasing demand for target-specific drugs, and high awareness related to polymyositis treatment & diagnosis.
Historical & Forecast Period
The polymyositis treatment market analyzed considering current market trends for base year 2018 and based on future trends CAGRs calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
This report covers the in-depth analysis of polymyositis treatment market covering market trends, strategies, and product lifecycle analyzed based on detailed qualitative and quantitative data collected through primary and secondary research. Industry stakeholders through primary interviews have assisted to study and understand market dynamics such as opportunities, drivers, & challenges further segmented to region & respective countries. This report also includes a comprehensive study of multiple segments of global polymyositis treatment such as the type of drug class, and geography. Pipeline analysis includes information related to molecules that are under clinical trial and expecting approval in the near future. The report also covers an understanding related to the competitive landscape of the major companies present in polymyositis treatment market that covers data points such as current/future business strategies, financial data, & product portfolio of respective companies.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2017-2027 |
| Base Year | 2018 |
| Forecast Period | 2019-2027 |
| Historical Year | 2017 |
| Unit | USD Million |
| Segmentation |
Type of Drug Class (2017–2027; US$ Mn) |
|
Pipeline Analysis |
|
|
Geography Segment (2017–2027; US$ Mn) |
The major companies present in the market studied based on recent market updates, product portfolio, financial data, and major strategies. This report also covers attractive investment proposition analyzed with the help of PESTEL analysis, which focuses on in-depth geographical research. Key players operating in the overall report are Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG, and Genentech, Inc. among others.
Key questions answered in this report
- Which drug class type is in high demand to treat polymyositis & Why?
- What are the present market strategies & policies studied & applied by key market players & competitive landscape of the global polymyositis treatment market?
- Which are the crucial & imminent geographical markets (regions and countries) in polymyositis treatment market & Why?
- Which is the largest and fastest growing region & country globally?
- What will be the expected sales of drugs under pipeline?
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global PT Market Portraiture
2.2. Global PT Market, by Type of Drug Class, 2018 (US$ Mn)
2.3. Global PT Market, by Geography, 2018 Vs 2027 (Value %)
Chapter 3. Global Polymyositis Treatment (PT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018
Chapter 4. Global Polymyositis Treatment (PT) Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Immunosuppressant
4.2.1. Methotrexate
4.2.2. Azathioprine
4.2.3. Cyclosporine
4.2.4. Tacrolimus
4.2.5. Mycophenolate
4.3. Alkylating Agent
4.3.1. Cyclophosphamide
4.3.2. Chlorambucil
4.4. Immunoglobulin
4.5. Monoclonal Antibodies
4.5.1. Rituximab
4.6. Corticosteroids
4.6.1. Prednisone
Chapter 5. Global Polymyositis Treatment (PT) Market: Pipeline Analysis
5.1. Overview
5.2. Phase III [Till 2027] (U$ Mn)
5.2.1. Ustekinumab
5.2.2. Abatacept
5.2.3. Lenabasum
5.2.4. Octagam 10%
5.2.5. Pirfenidone
5.3. Phase I & II (Qualitative Information)
5.3.1. Tocilizumab (Phase II)
5.3.2. PF-06823859 (Phase II)
5.3.3. IFN-Kinoid (Phase II)
5.3.4. JBT-101 (Phase II)
5.3.5. Tofacitinib (Phase I)
5.3.6. VIB7734 (Phase I)
Chapter 6. Global Polymyositis Treatment (PT) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America PT Market Analysis, 2017 – 2027
6.2.1. North America PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.2.2. North America PT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe PT Market Analysis, 2017 – 2027
6.3.1. Europe PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.3.2. Europe PT Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific PT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific PT Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America PT Market Analysis, 2017 – 2027
6.5.1. Latin America PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.5.2. Latin America PT Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) PT Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.6.2. MEA PT Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Hospira, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Antares Pharma, Inc.
7.3. Medexus Pharma, Inc.
7.4. Fresenius SE & Co. KGaA
7.5. Mylan N.V.
7.6. Alcami Corporation
7.7. Teva Pharmaceutical Industries Ltd.
7.8. Novartis AG
7.9. Genentech, Inc.
7.10. Bristol-Myers Squibb
7.11. Janssen Pharmaceutical
7.12. Corbus Pharmaceuticals Inc.
7.13. Octapharma
7.14. Beijing Continent Pharmaceutical Co, Ltd.
7.15. Pfizer, Inc.
7.16. Neovacs
7.17. Viela Bio
* Here we are using PT as a short form of Polymyositis Treatment
TABLE 1 Global Polymyositis Treatment (PT) Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 2 Global Immunosuppressant Market for PT, by Type of Immunosuppressant, 2017 – 2027 (US$ Mn)
TABLE 3 Global Alkylating Agent Market for PT, by Type of Alkylating Agents, 2017 – 2027 (US$ Mn)
TABLE 4 North America PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 5 North America PT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 6 Europe PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 7 Europe PT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 8 Asia Pacific PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 9 Asia Pacific PT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Latin America PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 11 Latin America PT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 Middle East & Africa PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 13 Middle East And Africa PT Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 Hospira, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Antares Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Medexus Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Fresenius SE & Co. KGaA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Alcami Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Genentech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Janssen Pharmaceutical: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Corbus Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Octapharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Beijing Continent Pharmaceutical Co, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Neovacs: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Viela Bio: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
FIG. 1 Polymyositis Treatment (PT): Market Segmentation
FIG. 2 Global PT Market, by Type of Drug Class, 2018 (US$ Mn)
FIG. 3 Global PT Market, by Geography, 2017 Vs 2027 (US$ Mn)
FIG. 4 Attractive Investment Proposition, by Geography, 2017
FIG. 5 Market Competition Landscape, by Key Players, 2017
FIG. 6 Global Methotrexate Market for PT, 2017 – 2027 (US$ Mn)
FIG. 7 Global Azathioprine Market for PT, 2017 – 2027 (US$ Mn)
FIG. 8 Global Cyclosporine Market for PT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Tacrolimus Market for PT Market, 2017 – 2027 (US$ Mn)
FIG. 10 Global Mycophenolate Market for PT Market, 2017 – 2027 (US$ Mn)
FIG. 11 Global Cyclophosphamide Market for PT, 2017 – 2027 (US$ Mn)
FIG. 12 Global Chlorambucil Market for PT, 2017 – 2027 (US$ Mn)
FIG. 13 Global Immunoglobulin Market for PT, 2017 – 2027 (US$ Mn)
FIG. 14 Global Rituximab Market for PT, 2017 – 2027 (US$ Mn)
FIG. 15 Global Prednisone Market for PT, 2017 – 2027 (US$ Mn)
FIG. 16 Global Ustekinumab Market for PT, Till 2027 (US$ Mn)
FIG. 17 Global Abatacept Market for PT, Till 2027 (US$ Mn)
FIG. 18 Global Lenabasum Market for PT, Till 2027 (US$ Mn)
FIG. 19 Global Octagam 10% Market for PT, Till 2027 (US$ Mn)
FIG. 20 Global Pirfenidone Market for PT, Till 2027 (US$ Mn)
FIG. 21 U.S. PT Market, 2017 – 2027 (US$ Mn)
FIG. 22 Canada PT Market, 2017 – 2027 (US$ Mn)
FIG. 23 U.K. PT Market, 2017 – 2027 (US$ Mn)
FIG. 24 Germany PT Market, 2017 – 2027 (US$ Mn)
FIG. 25 Rest Of Europe PT Market, 2017 – 2027 (US$ Mn)
FIG. 26 Japan PT Market, 2017 – 2027 (US$ Mn)
FIG. 27 China PT Market, 2017 – 2027 (US$ Mn)
FIG. 28 Rest Of Asia Pacific PT Market, 2017 – 2027 (US$ Mn)
FIG. 29 Brazil PT Market, 2017 – 2027 (US$ Mn)
FIG. 30 Mexico PT Market, 2017 – 2027 (US$ Mn)
FIG. 31 Rest Of Latin America PT Market, 2017 – 2027 (US$ Mn)
FIG. 32 GCC PT Market, 2017 – 2027 (US$ Mn)
FIG. 33 Rest Of Middle East And Africa PT Market, 2017 – 2027 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)